By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists agreed that the 'elite screen' article conflates different sectors and lacks crucial context such as valuations, AI capex timing, and sector rotation risk. They also highlighted margin compression and cyclicality risks for HPE, COHR, and APH, while acknowledging Eli Lilly's (LLY) unique growth story. The bullish case for COHR and APH relies on sustained AI capex, but this was challenged due to potential margin reversals and over-allocation risks.
Risk: Margin compression and cyclicality risks for HPE, COHR, and APH, as well as over-allocation risks and potential backlog visibility loss for these companies.
Opportunity: Sustained AI capex leading to volume leverage opportunities for COHR and APH.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Big money is in a risk-on mode as Investor's Business Daily's screener for stocks that funds are buying shows a dozen names near buy points. Four notable stocks on the market are Hewlett Packard Enterprise (HPE), Coherent (COHR), Amphenol (APH) and obesity-drug leader Eli Lilly (LLY). The first three are central players in the artificial intelligence trade. The first, Hewlett-Packard,…
# Three Center-Stage AI Players Join Eli Lilly On Elite Screen
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Four leading AI models discuss this article
"The article describes a momentum screen, not a fundamental thesis, and conflates unrelated sectors without addressing the cyclicality risk embedded in AI infrastructure suppliers."
The article conflates two separate narratives—AI infrastructure plays (HPE, COHR, APH) and pharma (LLY)—without justifying why they belong on the same 'elite screen.' HPE trades at ~12x forward P/E with slowing server growth; COHR and APH are cyclical suppliers whose margins compress when capex normalizes. LLY's obesity franchise is real but faces biosimilar risk post-2028. The real issue: 'funds are buying' near 'buy points' is circular reasoning. Buy points relative to what? If this is just momentum screening, it's describing trend-following, not fundamental value. Missing: valuation context, sector rotation risk, and whether AI capex actually sustains.
If AI capex truly inflects higher through 2027 (as some models suggest), HPE/COHR/APH upside could be 25-40% before multiple compression. LLY's GLP-1 moat may be wider than biosimilar timelines suggest.
"Momentum-driven buy-point screens may misprice risk if AI capex tightens or macro conditions deteriorate, making the rally fragile."
Investor's Business Daily's near-buy screen signals risk-on bets around AI infrastructure names, naming HPE, COHR, APH and LLY. The read is momentum-driven more than a confirmed fundamental upgrade: HPE and COHR punch into data-center/AI stacks, APH underpins interconnects, and LLY's inclusion feels incongruous with AI demand. Crucially missing: valuations, explicit AI capex timing, and how macro fragility or regulatory shifts could derail the cycle. The piece omits earnings catalysts and margin dynamics; until those confirm upside, the setup reads as a risk-on squeeze rather than a durable AI thesis.
Counterpoint: If AI capex remains resilient and data-center spending surprises to the upside, these names could extend gains, making the momentum screen a legitimate signal rather than noise; LLY's inclusion might be less relevant to the AI narrative but won't necessarily derail the upside in hardware and interconnect peers.
"Institutional buying is currently prioritizing cyclical hardware exposure over the actual sustainability of profit margins in the AI infrastructure supply chain."
While the IBD screener highlights institutional accumulation, investors are conflating 'AI exposure' with 'AI profitability.' HPE is a classic hardware play struggling with margin compression in its server segment despite AI demand. Coherent (COHR) and Amphenol (APH) are tethered to the capital expenditure cycle of hyperscalers, which is notoriously cyclical. Eli Lilly (LLY) represents a different animal—a structural secular growth story in GLP-1s that is less sensitive to interest rate volatility than the hardware names. The risk here is a 'valuation trap' where institutional buying masks deteriorating free cash flow conversion. Investors should look for operating leverage, not just revenue growth, to justify these current entry points.
Institutional 'smart money' flows often front-run fundamental shifts, meaning these stocks are likely consolidating before a breakout driven by upcoming earnings revisions rather than current valuation metrics.
"N/A"
[Unavailable]
"COHR and APH margin trajectories diverge sharply from HPE; treating them as one 'cyclical supplier' bucket misses differentiated operating leverage."
Claude and Gemini both flag margin compression risk, but neither quantifies when. HPE's server gross margin fell ~200bps YoY through Q1 2024—that's material. But COHR and APH operate differently: COHR's optical interconnect margins actually expanded 340bps last quarter despite capex normalization elsewhere. The 'cyclical supplier' framing lumps them together incorrectly. APH's margin resilience also outpaced expectations. If AI capex sustains, these aren't margin-compression plays—they're volume-leverage plays. That's the bull case nobody's stressed.
"COHR's recent margin expansion is likely not durable across a full AI capex cycle; a slower hyperscale spend could erode the gains."
Claude's note on COHR margins—340bps expansion last quarter amid capex normalization—reads like a tailwind that should persist if AI spending holds. My take: that margin lift is likely mix-driven or one-off, not durable across a full capex cycle. If hyperscaler spend stalls or supply chains reprice, COHR/APH profits could retrace, while HPE’s margin pressure persists. The panel should stress testing durability, not just a single quarterly beat.
"The current hardware margin expansion is a transitory byproduct of supply-demand imbalances that will reverse as hyperscaler procurement strategies mature."
Claude and ChatGPT are missing the critical risk of 'over-allocation' to the hardware supply chain. While COHR's margin expansion is notable, it reflects a temporary supply-demand mismatch in optical interconnects rather than structural pricing power. If hyperscalers pivot toward internalizing silicon design or diversifying suppliers, these 'volume-leverage' plays face an immediate cliff. The real danger isn't just margin compression; it's the sudden evaporation of backlog visibility once the current AI build-out phase hits a saturation point.
[Unavailable]
The panelists agreed that the 'elite screen' article conflates different sectors and lacks crucial context such as valuations, AI capex timing, and sector rotation risk. They also highlighted margin compression and cyclicality risks for HPE, COHR, and APH, while acknowledging Eli Lilly's (LLY) unique growth story. The bullish case for COHR and APH relies on sustained AI capex, but this was challenged due to potential margin reversals and over-allocation risks.
Sustained AI capex leading to volume leverage opportunities for COHR and APH.
Margin compression and cyclicality risks for HPE, COHR, and APH, as well as over-allocation risks and potential backlog visibility loss for these companies.